Literature DB >> 29294478

Correction: The Increasing Burden of Imported Chronic Hepatitis B - United States, 1974-2008.

Tarissa Mitchell, Gregory L Armstrong, Dale J Hu, Annemarie Wasley, John A Painter.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0027717.].

Entities:  

Year:  2013        PMID: 29294478      PMCID: PMC5769802          DOI: 10.1371/annotation/7f73ed17-709e-4d7f-9aae-aab1f4a34985

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


There are changes to the second through fifth sentences of the fifth paragraph of the Discussion section. The section should be: Immigrants are required to receive ACIP-recommended vaccines during the exam; therefore, immigrating children receive hepatitis B vaccine [21]. The ACIP currently recommends screening prior to vaccination for all persons born in high-endemicity countries.* The ACIP also recommends hepatitis B vaccine for certain groups of at-risk adults*, but makes no specific recommendation for vaccination of adult immigrants from intermediate- or high-endemicity countries. *[CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 2: immunization of adults. MMWR 2006;55(No. RR-16), p. 27-28].
  2 in total

1.  Challenges with hepatitis B vaccination of high risk adults - A pilot program.

Authors:  Carolyn B Bridges; Tureka L Watson; Noele P Nelson; Maribel Chavez-Torres; Patrick Fineis; Boatemaa Ntiri-Reid; Edward Wake; Judith M Leahy; Anita K Kurian; Mary Ann K Hall; Erin D Kennedy
Journal:  Vaccine       Date:  2019-07-11       Impact factor: 3.641

2.  Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.

Authors:  Haesuk Park; Donghak Jeong; Pauline Nguyen; Linda Henry; Joseph Hoang; Yoona Kim; Edward Sheen; Mindie H Nguyen
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.